These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 18830927)

  • 1. Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes.
    Hinke SA
    Curr Opin Mol Ther; 2008 Oct; 10(5):516-25. PubMed ID: 18830927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does immune-tolerance treatment with Alum-formulated GAD65 protect insulin-production in the pancreatic islet β cells?
    Larsson HE; Lernmark A
    Hum Vaccin; 2011 Jan; 7(1):45-9. PubMed ID: 21263221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GAD-alum immunotherapy in Type 1 diabetes mellitus.
    Morales AE; Thrailkill KM
    Immunotherapy; 2011 Mar; 3(3):323-32. PubMed ID: 21395375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GAD-alum (Diamyd)--a new concept for preservation of residual insulin secretion.
    Ludvigsson J
    Expert Opin Biol Ther; 2010 May; 10(5):787-99. PubMed ID: 20230187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65).
    Axelsson S; Hjorth M; Akerman L; Ludvigsson J; Casas R
    Diabetes Metab Res Rev; 2010 Oct; 26(7):559-68. PubMed ID: 20830731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy with GAD in diabetes.
    Ludvigsson J
    Diabetes Metab Res Rev; 2009 May; 25(4):307-15. PubMed ID: 19267332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.
    Axelsson S; Chéramy M; Akerman L; Pihl M; Ludvigsson J; Casas R
    Diabetes Care; 2013 Nov; 36(11):3418-24. PubMed ID: 23863909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.
    Ludvigsson J; Chéramy M; Axelsson S; Pihl M; Akerman L; Casas R;
    Diabetes Metab Res Rev; 2014 Jul; 30(5):405-14. PubMed ID: 24302596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes.
    Agardh CD; Cilio CM; Lethagen A; Lynch K; Leslie RD; Palmér M; Harris RA; Robertson JA; Lernmark A
    J Diabetes Complications; 2005; 19(4):238-46. PubMed ID: 15993359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2.
    Nowak C; Lind M; Sumnik Z; Pelikanova T; Nattero-Chavez L; Lundberg E; Rica I; Martínez-Brocca MA; Ruiz de Adana M; Wahlberg J; Hanas R; Hernandez C; Clemente-León M; Gómez-Gila A; Ferrer Lozano M; Sas T; Pruhova S; Dietrich F; Puente-Marin S; Hannelius U; Casas R; Ludvigsson J
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2644-2651. PubMed ID: 35665810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 1-year pilot study of intralymphatic injections of GAD-alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes.
    Hals IK; Balasuriya C; Casas R; Ludvigsson J; Björklund A; Grill V
    Diabetes Obes Metab; 2023 Nov; 25(11):3400-3409. PubMed ID: 37580967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination.
    Bekris LM; Jensen RA; Lagerquist E; Hall TR; Agardh CD; Cilio CM; Lethagen AL; Lernmark A; Robertson JA; Hampe CS
    Diabet Med; 2007 May; 24(5):521-6. PubMed ID: 17367313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.
    Ludvigsson J; Krisky D; Casas R; Battelino T; Castaño L; Greening J; Kordonouri O; Otonkoski T; Pozzilli P; Robert JJ; Veeze HJ; Palmer J; Samuelsson U; Elding Larsson H; Åman J; Kärdell G; Neiderud Helsingborg J; Lundström G; Albinsson E; Carlsson A; Nordvall M; Fors H; Arvidsson CG; Edvardson S; Hanås R; Larsson K; Rathsman B; Forsgren H; Desaix H; Forsander G; Nilsson NÖ; Åkesson CG; Keskinen P; Veijola R; Talvitie T; Raile K; Kapellen T; Burger W; Neu A; Engelsberger I; Heidtmann B; Bechtold S; Leslie D; Chiarelli F; Cicognani A; Chiumello G; Cerutti F; Zuccotti GV; Gomez Gila A; Rica I; Barrio R; Clemente M; López Garcia MJ; Rodriguez M; Gonzalez I; Lopez JP; Oyarzabal M; Reeser HM; Nuboer R; Stouthart P; Bratina N; Bratanic N; de Kerdanet M; Weill J; Ser N; Barat P; Bertrand AM; Carel JC; Reynaud R; Coutant R; Baron S
    N Engl J Med; 2012 Feb; 366(5):433-42. PubMed ID: 22296077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes.
    Agardh CD; Lynch KF; Palmér M; Link K; Lernmark A
    Diabetologia; 2009 Jul; 52(7):1363-8. PubMed ID: 19404608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial.
    Ludvigsson J; Hjorth M; Chéramy M; Axelsson S; Pihl M; Forsander G; Nilsson NÖ; Samuelsson BO; Wood T; Aman J; Ortqvist E; Casas R
    Diabetologia; 2011 Mar; 54(3):634-40. PubMed ID: 21116604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GAD-specific T cells are induced by GAD-alum treatment in Type-1 diabetes patients.
    Pihl M; Barcenilla H; Axelsson S; Chéramy M; Åkerman L; Johansson I; Ludvigsson J; Casas R
    Clin Immunol; 2017 Mar; 176():114-121. PubMed ID: 28131926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of gamma aminobutyric acid (GABA) or GABA with glutamic acid decarboxylase (GAD) on the progression of type 1 diabetes mellitus in children: Trial design and methodology.
    Choat HM; Martin A; Mick GJ; Heath KE; Tse HM; McGwin G; McCormick KL
    Contemp Clin Trials; 2019 Jul; 82():93-100. PubMed ID: 31229619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Etanercept, GAD-alum and vitamin D treatment: an open pilot trial to preserve beta cell function in recent onset type 1 diabetes.
    Ludvigsson J; Routray I; Vigård T; Hanås R; Rathsman B; Carlsson A; Särnblad S; Albin AK; Arvidsson CG; Samuelsson U; Casas R
    Diabetes Metab Res Rev; 2021 Oct; 37(7):e3440. PubMed ID: 33486892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High titre of antiglutamic acid decarboxylase autoantibody is a strong predictor of the development of thyroid autoimmunity in patients with type 1 diabetes and latent autoimmune diabetes in adults.
    Jin P; Huang G; Lin J; Yang L; Xiang B; Zhou W; Zhou Z
    Clin Endocrinol (Oxf); 2011 May; 74(5):587-92. PubMed ID: 21470281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adult-onset latent autoimmune diabetes and autoimmune thyroid disease].
    Jin P; Zhou ZG; Yang L; Yan X; Wang JP; Zhang DM; Huang G
    Zhonghua Nei Ke Za Zhi; 2004 May; 43(5):363-7. PubMed ID: 15182509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.